Veillon-Berteloot Chantal 4

What Happened

• Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences (IART), was granted 41,783 restricted stock units (RSUs) on 2026-03-11 and, on the same date, had 5,420 shares disposed of at $9.61/share (totaling $52,086) to satisfy tax withholding or exercise-related tax liability. The RSU grant is reported as a derivative acquisition (reported value $0.00 on the Form 4).

Key Details

• Transaction dates: 2026-03-11 (both the RSU grant and the share disposition); Form 4 filed 2026-03-12 (timely).
• Disposition: 5,420 shares sold/withheld at $9.61 each, proceeds $52,086 (transaction code F — tax withholding).
• Acquisition: 41,783 RSUs granted (transaction code A — award/grant); reported acquisition value $0.00 on the filing because these are derivative awards.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The RSUs vest 33% on the 1st and 2nd anniversaries and 34% on the 3rd anniversary of the grant date (3/11/2026).

Context

• This is a typical executive equity grant combined with a tax-withholding share disposition. The RSU grant is a deferred award subject to multi-year vesting; the share disposition was to cover tax obligations and does not necessarily indicate a directional view on the stock. The filing was submitted the next day, which is within normal Form 4 timing rules.